Attached files
file | filename |
---|---|
10-K - 10-K - Zynerba Pharmaceuticals, Inc. | zyne-20161231x10k.htm |
EX-32.2 - EX-32.2 - Zynerba Pharmaceuticals, Inc. | zyne-20161231ex32211e9ae.htm |
EX-32.1 - EX-32.1 - Zynerba Pharmaceuticals, Inc. | zyne-20161231ex321a1d80e.htm |
EX-31.2 - EX-31.2 - Zynerba Pharmaceuticals, Inc. | zyne-20161231ex312dfdca7.htm |
EX-31.1 - EX-31.1 - Zynerba Pharmaceuticals, Inc. | zyne-20161231ex3112d6b06.htm |
EX-21.1 - EX-21.1 - Zynerba Pharmaceuticals, Inc. | zyne-20161231ex2118906b5.htm |
EX-10.7 - EX-10.7 - Zynerba Pharmaceuticals, Inc. | zyne-20161231ex107969c19.htm |
EX-10.26 - EX-10.26 - Zynerba Pharmaceuticals, Inc. | zyne-20161231ex102645e4a.htm |
EX-10.18 - EX-10.18 - Zynerba Pharmaceuticals, Inc. | zyne-20161231ex101817e7a.htm |
EX-10.17 - EX-10.17 - Zynerba Pharmaceuticals, Inc. | zyne-20161231ex1017059c2.htm |
Exhibit 23.1
Consent Of Independent Registered Public Accounting Firm
The Board of Directors
Zynerba Pharmaceuticals, Inc.:
We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333-207973) and Form S-3 (No. 333-213430) of Zynerba Pharmaceuticals, Inc. of our report dated March 27, 2017, with respect to the consolidated balance sheets of Zynerba Pharmaceuticals, Inc. as of December 31, 2016 and 2015, and the related consolidated statements of operations, redeemable convertible preferred stock, convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2016, which report appears in the December 31, 2016 annual report on Form 10-K of Zynerba Pharmaceuticals, Inc.
/s/ KPMG LLP |
Philadelphia, PA |
March 27, 2017 |